Aim immunotech to participate in the virtual investor summer spotlight series

Ocala, fla., july 05, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including covid-19, the disease caused by the sars-cov-2 virus, today announced that thomas k.
AIM Ratings Summary
AIM Quant Ranking